Jpmorgan Chase & CO Aldeyra Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 27,544 shares of ALDX stock, worth $59,219. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,544

Previous 25,394 8.47%

Holding current value

$59,219

Previous $126,000 25.4%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$4.7 - $6.98 $10,105 - $15,007	2,150 Added 8.47%	27,544 $158,000
Q4 2024 Feb 12, 2025	BUY	$4.21 - $5.9 $6,643 - $9,310	1,578 Added 6.63%	25,394 $126,000
Q3 2024 Dec 26, 2024	BUY	$3.19 - $6.32 $6,006 - $11,900	1,883 Added 8.59%	23,816 $128,000
Q3 2024 Nov 08, 2024	BUY	$3.19 - $6.32 $6,006 - $11,900	1,883 Added 8.59%	23,816 $128,000
Q2 2024 Dec 26, 2024	SELL	$3.25 - $4.72 $6,119 - $8,887	-1,883 Reduced 7.91%	21,933 $72,000
Q2 2024 Aug 12, 2024	BUY	$3.25 - $4.72 $8,099 - $11,762	2,492 Added 12.82%	21,933 $72,000
Q1 2024 Dec 26, 2024	SELL	$2.77 - $4.22 $12,118 - $18,462	-4,375 Reduced 18.37%	19,441 $63,000
Q1 2024 May 10, 2024	SELL	$2.77 - $4.22 $33,899 - $51,644	-12,238 Reduced 38.63%	19,441 $63,000
Q4 2023 Dec 26, 2024	BUY	$1.47 - $6.06 $11,558 - $47,649	7,863 Added 33.02%	31,679 $111,000
Q4 2023 Feb 12, 2024	SELL	$1.47 - $6.06 $364 - $1,502	-248 Reduced 0.78%	31,679 $111,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $27,519 - $36,752	-4,504 Reduced 12.36%	31,927 $213,000
Q2 2023 Aug 11, 2023	BUY	$7.11 - $11.89 $258,505 - $432,296	36,358 Added 49805.48%	36,431 $305,000
Q4 2022 Feb 13, 2023	SELL	$5.08 - $7.09 $101 - $141	-20 Reduced 21.51%	73 $1,000
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $76 - $154	20 Added 27.4%	93 $0
Q2 2022 Aug 11, 2022	SELL	$2.43 - $4.85 $55,311 - $110,395	-22,762 Reduced 99.68%	73 $0
Q1 2022 May 11, 2022	BUY	$3.25 - $5.17 $13,039 - $20,742	4,012 Added 21.31%	22,835 $101,000
Q4 2021 Feb 10, 2022	BUY	$3.5 - $9.63 $2,912 - $8,012	832 Added 4.62%	18,823 $75,000
Q3 2021 Nov 12, 2021	BUY	$7.94 - $11.31 $142,848 - $203,478	17,991 New	17,991 $158,000

Others Institutions Holding ALDX

# of Institutions

139

Shares Held

38.6M

Call Options Held

620K

Put Options Held

435K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $125M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Aldeyra Therapeutics, Inc. Transaction History